Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIL1: Pirfenidone in RA-ILD
NCT02808871Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease (RA-ILD), sponsored by Brigham and Women's Hospital. Started Apr 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
Beyond the preview
Go deeper on NCT02808871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808871.